Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlumisALMS -4.71%12 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 835 Biotechnology companies, Alumis ranks worse than 119760.36% on this metric.
Alumis's average Accounts Receivable for the
three
months ended in Jun. 2026 was $0.00 Mil. Alumis's Revenue for the
three
months ended in Jun. 2026 was $1.66 Mil.
Hence, Alumis's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Alumis's Days Sales Outstanding or its related term are showing as below:
ALMS's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.95 * Ranked among companies with meaningful Days Sales Outstanding only.
Alumis's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Alumis (NAS:ALMS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Alumis Days Sales Outstanding Related Terms
Alumis Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Alumis's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALMS vs RCUS, DNLI, NAMS: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Alumis's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alumis Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alumis's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Alumis's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alumis (ALMS) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Alumis and its competitors. According to the industry distribution chart, Alumis ranks #999999 out of 835 companies in the Biotechnology industry.
Is Alumis' Days Sales Outstanding too high?
Alumis' current Days Sales Outstanding is 0.00. Based on the distribution chart, Alumis ranks #999999 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' Days Sales Outstanding compare to RCUS and DNLI?
According to the Biotechnology industry distribution chart, Alumis ranks #999999 out of 835 companies for Days Sales Outstanding. This places Alumis in the lower half of its industry. The industry median Days Sales Outstanding is 68.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.95, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Alumis and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alumis's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Alumis' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Alumis (ALMS), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score
Get the complete analysis for ALMS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMS has been successfully added to your 
